Nexstim (NXTMH) Life Science Summit 2025 summary

Business overview and technology

• Focuses on personalized brain diagnostics and therapy using proprietary navigated transcranial magnetic stimulation (TMS) technology.

• Integrated system (NBS 6) serves diagnostics, therapy, and research, with recent version approved in October.

• Only navigated TMS device with both FDA and CE approvals for pre-surgical mapping of motor and speech areas.

• Over 250 systems sold for diagnostics and 121 for therapy, with strong presence in research and neuroscience.

• Therapy applications include depression and chronic pain, with reimbursement available in the US.

Growth, financials, and profitability

• Average sales growth of 39% over the reported period, with gross margins at 79%.

• EBITDA positive results achieved, with margins and profits outpacing expenses.

• 45% revenue growth in the first nine months of 2025 compared to the same period in 2024.

• Recurring revenue from service contracts, consumables, and spare parts supports financial stability.

• Transitioned from early-stage to scale-up phase, focusing on further scaling opportunities.

Strategic partnerships and market expansion

• Partnership with Brainlab enhances global neurosurgical market access and visibility.

• Collaboration with Synaptica Therapeutics explores TMS and EEG for Alzheimer's treatment, showing promising early data.

• Participation in international events and conferences increases exposure to neurosurgeons worldwide.

• Modular system design allows for future feature and indication expansion.

• Actively pursuing regulatory approvals in Japan and China for long-term growth.